How might these costs, the NLA’s recommendation, and the supporting clinical evidence factor into payer decisions about whether to cover Lp(a) testing? Related Videos Related Content ...

The RM5bil factoring allocation, which was announced after MFA’s 37th annual general meeting yesterday, will be offered to qualified companies for the new term from 2023 to 2024.